News Releases

Dec. 25, 2001

Sumitomo Pharmaceutical Co., Ltd. concludes an agreement with LifeSpan BioSciences, Inc., obtaining access to the latter's GPCR expression and localization database.

On December 21, 2001 Sumitomo Pharmaceuticals Co., Ltd. entered into a subscription agreement with LifeSpan BioSciences Inc. (LifeSpan) to access LifeSpan's database of information on the expression and localization of G protein-coupled receptors (GPCRs). Sumitomo Pharmaceuticals has subscribed to the GPCR database in order to strengthen its genome information-based drug discovery.

LifeSpan BioSciences, founded in 1995 in Seattle, Washington, U.S.A., is a leading proteomics company. Its consortium-type GPCR expression and localization database integrates data of interest to each participating company into a single relational database. The database contains detailed information on the expression and localization of more than 300 GPCRs in normal and diseased human tissues. By using immunohistochemistry with specific antibodies to stain specimens from its extensive tissue bank, LifeSpan is able to localize expression of GPCR proteins to individual cell types within normal and diseased tissues and to correlate changes in expression with disease status.

The agreement gives Sumitomo Pharmaceuticals secure encrypted access to Lifespan's database via the Internet.

G protein-coupled receptors are a large family of specific receptors present in the cell membrane. They are attracting considerable attention as new drug targets , because they act as the receptors through which many physiologically active substances, including hormones and neurotransmitters, express their activity, and they are the sites of action for many important drugs.

In its research on the selection and evaluation of new drug targets, Sumitomo Pharmaceuticals will apply Lifespan's GPCR database to obtain information about the proteins encoded by the GPCR genes that are discovered through Incyte Genomics' gene sequence database and Gene Logic's gene expression database.

Sumitomo Pharmaceuticals has been conducting – primarily at the Genomic Science Laboratory established jointly with Sumitomo Chemical Co., Ltd. – genome-related research which includes the search for and analysis of the functions of new drug targets (proteins), and investigation into the action mechanisms and predicting adverse effects of drug candidate compounds. This agreement with Lifespan is expected to strengthen Sumitomo Pharmaceutical's research into drug discovery, using genomic information.